Oleanolic Acid Acetate Mitigates Cisplatin Nephrotoxicity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Platinum-based anticancer drugs like Cisplatin cause significant nephrotoxicity, leading to severe kidney damage and toxicity, necessitating the development of effective pharmacological approaches to mitigate this side effect.

Innovation Solution

The use of oleanolic acid acetate, derived from adzuki beans, as a pharmaceutical composition or health functional food, which reduces BUN values, inflammatory cytokine levels, and inflammatory factor expression in kidney tissue, thereby inhibiting nephrotoxicity induced by platinum-based anticancer drugs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If platinum-based anticancer drugs like Cisplatin are used to treat cancer, then anticancer effects are achieved through DNA cross-linking and cell division inhibition, but severe nephrotoxicity and kidney damage occur due to drug accumulation in the kidneys

Engineering Contradiction:

Improveanticancer effectVSAvoidnephrotoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses oleanolic acid acetate as a protective intermediary substance that mediates between the anticancer drug Cisplatin and the kidney tissue. This compound prevents direct toxic interaction between Cisplatin and renal cells while allowing the drug to maintain its anticancer activity, thereby resolving the contradiction between therapeutic efficacy and renal safety

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies prior cushioning by administering oleanolic acid acetate before Cisplatin treatment to pre-protect kidney cells from upcoming toxic damage. This preventive approach cushions the kidneys against the harmful effects of Cisplatin accumulation before the toxicity can occur, while the anticancer treatment proceeds as planned

Inventive Principle:

Principle #11Beforehand cushioning (Prior cushioning)

2Reliability

If the dose of Cisplatin is increased to enhance anticancer efficacy, then DNA adduct formation and cell division inhibition are improved, but nephrotoxicity increases in proportion to the dose administered

Engineering Contradiction:

Improveanticancer efficacyVSAvoidrenal toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Oleanolic acid acetate serves as a dose-independent protective intermediary that allows higher Cisplatin dosing without proportional increase in kidney damage. The compound creates a protective buffer that decouples the relationship between drug dose and renal toxicity, enabling enhanced anticancer efficacy without linearly increasing nephrotoxic risk

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If pharmacological approaches are used to reduce Cisplatin-induced nephrotoxicity, then kidney protection may be improved, but treatment complexity and additional medication requirements increase

Engineering Contradiction:

Improvenephrotoxicity reductionVSAvoidtreatment regimen complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

Oleanolic acid acetate demonstrates multi-functionality by simultaneously protecting kidney cells from Cisplatin toxicity while not interfering with the drug's anticancer mechanism. This single compound addresses multiple concerns (renal protection, maintenance of therapeutic efficacy) without requiring complex multi-drug regimens, thereby reducing overall treatment complexity

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Oleanolic acid acetate effectively reduces nephrotoxicity by decreasing BUN values and inflammatory markers, offering a safe and effective treatment for drug-induced kidney damage without significant cytotoxicity, thus improving treatment outcomes for cancer patients.

Implementation Method 1

oleanolic acid acetate effectively reduces nephrotoxicity by decreasing BUN values and inflammatory markers

Methodology Applied

Scientific EffectAnti-inflammatory effect:

Implementation Method 2

oleanolic acid acetate effectively reduces nephrotoxicity by decreasing BUN values and inflammatory markers, offering a safe and effective treatment for drug-induced kidney damage

Methodology Applied

Scientific EffectNephroprotective effect:

Data Source

PatentUS11464787B2Composition comprising oleanolic acid acetate as active ingredient for preventing, alleviating, or treating renal toxicity induced by medicine

Publication Date: 2022.10.11 KOREA RES INST OF BIOSCIENCE & BIOTECHNOLOGY

AI summary

The present invention relates to a composition for preventing, improving or treating drug-induced nephrotoxicity, the composition comprising oleanolic acid acetate as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating drug-induced nephrotoxicity comprising oleanolic acid acetate or a pharmaceutically acceptable salt thereof as an active ingredient, a health functional food for preventing or improving drug-induced nephrotoxicity comprising the active ingredients, and an anticancer adjuvant comprising the active ingredients. The oleanolic acid acetate of the present invention is derived from a natural product and has no side effects and no cytotoxicity and has excellent effects of preventing, improving and treating nephrotoxicity caused by a drug, particularly a platinum-based anticancer drug, so that it can be utilized as a pharmaceutical composition, a health functional food, and a cancer adjuvant thereof.